Anemia of prematurity

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anemia of prematurity
Classification and external resources
ICD-10 P61.2
ICD-9 776.6
eMedicine article/978238

Anemia of prematurity refers to a form of anemia affecting preterm infants[1] with decreased hematocrit.[2]

Pathophysiology[edit]

Preterm infants are often anemic and typically experience heavy blood losses from frequent laboratory testing in the first few weeks of life. Although their anemia is multifactorial, repeated blood sampling and reduced erythropoiesis with extremely low serum levels of erythropoietin (EPO) are major determining factors.[3][4][5] Blood sampling done for laboratory testing can easily remove enough blood to produce anemia. Obladen, Sachsenweger and Stahnke (1987) studied 60 very low birth weight infants during the first 28 days of life. Infants were divided into 3 groups, group 1 (no ventilator support, 24 ml/kg blood loss), group 2(minor ventilated support, 60 ml/kg blood loss), and group 3(ventilated support for respiratory distress syndrome, 67 ml/kg blood loss). Infants were checked for clinical symptoms and laboratory signs of anemia 24 hours before and after the blood transfusion. The study found that groups 2 and 3 who had significant amount of blood loss, showed poor weight gain, pallor and distended abdomen. These reactions are the most frequent symptoms of anemia.[6]

During the first weeks of life, all infants experience a decline in circulating red blood cell (RBC) volume generally expressed as blood hemoglobin concentration (Hb).[7] As anemia develops, there is even more of a significant reduction in the concentration of hemoglobin.[8] Normally this stimulates a significant increased production of erythropoietin (EPO), but this response is diminished in premature infants. Dear, Gill, Newell, Richards and Schwarz (2005) conducted a study to show that there is a weak negative correlation between EPO and Hb. The researchers recruited 39 preterm infants from 10 days of age or as soon as they could manage without respiratory support. They estimated total EPO and Hb weekly and 2 days after a blood transfusion. The study found that when Hb>10, EPO mean was 20.6 and when Hb≤10, EPO mean was 26.8. As Hb goes down, EPO goes up.[9] While the reason for this decreased response is not fully understood, Strauss (n.d.) states that it results from both physiological factors (e.g., the rapid rate of growth and need for a commensurate increase in RBC mass to accompany the increase in blood volume) and, in sick premature infants, from phlebotomy blood losses. In premature infants this decline occurs earlier and more pronounced that it does in healthy term infants. Healthy term infants Hb rarely falls below 9 g/dL at an age of approximately 10–12 weeks, while in premature infants, even in those without complicating illnesses, the mean Hb falls to approximately 8g/dL in infants of 1.0-1.5 kg birth weight and to 7g/dL in infants <1.0 kg. Because this postnatal drop in hemoglobin level is universal and is well tolerated in term infants, it is commonly referred to as the “physiologic” anemia of infancy. However, in premature infants the decline in Hb may be associated with abnormal clinical signs severe enough to prompt transfusions.[citation needed]

Treatment[edit]

Transfusion[edit]

AOP is usually treated by blood transfusion but the indications for this are still unclear. Blood transfusions have the risk of incompatibility and transfusion reactions as well as viral infections. Also, blood transfusions are costly and add to parental anxiety. The best treatment in prevention is minimizing the amount of blood drawn from the infant. It is found that since blood loss attributable to laboratory testing is the primary cause of anemia among preterm infants during the first weeks of life, we quantified blood lost attributable to phlebotomy overdraw, something that might be avoided. A study was done to see when and if overdraw was a problem. They recorded all of the data that could be of influence such as the test performed, the blood collection container used, the infants location (neonatal intensive care unit (NICU) and intermediate intensive care unit), the infant’s weight sampling and the phlebotomist’s level of experience, work shift, and clinical role. Infants were classified by weight into 3 groups: <1 kg, 1 to 2 kg, and >2 kg. The volume of blood removed was calculated by subtracting the weight of the empty collection container from that of the container filled with blood. They found that the mean volume of blood drawn for the 578 tests exceeded that requested by the hospital laboratory by 19.0% ± 1.8% per test. The main factors of overdraw was: collection in blood containers without fill-lines, lighter weight infants and critically ill infants being cared for in the NICU.[citation needed]

EPO[edit]

Recombinant EPO (r-EPO) may be given to premature infants to stimulate red blood cell production. Brown and Keith (1999) studied two groups of 40 very low birth weight (VLBW) infants to compare the erythropoietic response between two and five times a week dosages of recombinant human erythropoietin (r-EPO) using the same dose. They established that more frequent dosing of the same weekly amount of r-EPO generated a significant and continuous increase in Hb in VLBW infants. The infants that received five dosages had 219,857 mm³ while infants that received two dosages only had 173,361 mm³. However, the response to r-EPO typically takes up to two weeks and the higher dosages lead to higher Hb. Brown and Keith (1999) study also showed responses between two dosage schedules (two times a week and five times a week). Infants were recruited for gestational age—age since conception—≤27 weeks and 28 to 30 weeks and then randomized into the two groups, each totaling 500 U/kg a week. Brown and Keith found that after two weeks of r-EPO administration, Hb counts had increased and leveled off; the infants who received r-EPO five times a week had significantly higher Hb counts. This was present at four weeks for all infants ≤30 weeks gestation and at 8 weeks for infants ≤27 weeks gestation.[10]

To date, studies of r-EPO use in premature infants have had mixed results. Ohls et al. examined the use of early r-EPO plus iron and found no short-term benefits in two groups of infants (172 infants less than 1000 g and 118 infants 1000–1250 g). All r-EPO treated infants received 400 U/g three times a week until they reached 35 weeks gestational age. The use of r-EPO did not decrease the average number of transfusions in the infants born at less than 1000 g, or the percentage of infants in the 1000 to 1250 group. A multi-center European trial studied early versus late r-EPO in 219 infants with birth weights between 500 and 999 g. An r-EPO close of 750 U/kg/week was given to infants in both the early (1–9 weeks) and late (4–10 weeks) groups. The two r-EPO groups were compared to a control group who did not receive r-EPO. Infants in all three groups received 3 to 9 mg/kg of enteral iron. These investigators reported a slight decrease in transfusion and donor exposures in the early r-EPO group (1–9 weeks): 13% early, 11% late and 4% control group.[11] It is likely that only a carefully selected subpopulation of infants may benefit from its use. Contrary to what just said, Bain and Blackburn (2004) also state in another study the use of r-EPO does not appear to have a significant effect on reducing the numbers of early transfusions in most infants, but may be useful to reduce numbers of late transfusion in extremely low-birth-weight infants. A British task force to establish transfusion guidelines for neonates and young children and to help try to explain this confusion recently concluded that “the optimal dose, timing, and nutritional support required during EPO treatment has yet to be defined and currently the routine use of EPO in this patient population is not recommended as similar reduction in blood use can probably be achieved with appropriate transfusion protocols.”[citation needed]

Transfusion management[edit]

Other strategies involve the reduction of blood loss during phlebotomy.[12]

Another treatment used is therapeutic strategies. These strategies are aimed at reducing transfusions have assessed the use of strict blood transfusions guidelines and EPO therapy, but reduction of blood loss is most important.[citation needed] For extremely low birth weight infants, laboratory blood testing using bedside devices offers a unique opportunity to reduce blood transfusions. This practice has been referred to as point-of-care testing. Use of these kind of devices to measure the most common ordered blood tests could significantly decrease phlebotomy loss and lead to a reduction in the need for blood transfusions among critically ill premature neonates. A study was done by Adams, Benitz, Geaghan, Kumar, Madan and Widness (2005) to test this theory by conducting a retrospective chart review on all inborn infants <1000g admitted to the NICU during two separate years. Conventional bench top laboratory analysis during the first year was done using Radiometer Blood Gas and Electrolyte Analyzer. Bedside blood gas analysis during the second year was performed using a point-of-care analyzer. An estimated blood loss in the two groups was determined based on the number of specific blood tests on individual infants. The study found that there was an estimated 30% reduction in the total volume of blood removed for the blood tests. This study concluded that there is modern technology that can be used instead of blood transfusions and r-EPO.[citation needed]

See also[edit]

References[edit]

  1. ^ Widness JA (November 2008). "Pathophysiology of Anemia During the Neonatal Period, Including Anemia of Prematurity". Neoreviews 9 (11): e520. doi:10.1542/neo.9-11-e520. PMC 2867612. PMID 20463861. 
  2. ^ "Anemia of prematurity". Retrieved 2010-05-31. 
  3. ^ Adams, M., Benitz, W., Geaghan, S., Kumar, R., Madan, A., & Widness, J. (2005). Reduction in red blood cell transfusions using a bedside analyzer in extremely low birth weight infants. Journal of Perinatology 25, 21-25. Retrieved November 16, 2007, from EbscoHost Research Databases.
  4. ^ Astruc, D., Donato, L., Haddad, J., Matis, J., & Messer, J. (1993). Early treatment of premature infants with recombinant human erythropoietin. Pediatrics 92(4), 519-523. Retrieved December 9, 2007, from EbscoHost Research Databases
  5. ^ Connolly, N., Cress, G., Johnson, K., Kulhavy, J., Lin, J., Strauss, R., Widness, J., & Zimmerman, M. (2000). Phlebotomy overdraw in the neonatal intensive care nursery. Pediatrics 106(2), 19. Retrieved November 16, 2007, from EbscoHost Research Databases.
  6. ^ Obladen, M., Sachsenweger, M., & Stahnke, M. (1988). Blood sampling in very low birth weight infants receiving different levels of intensive care. Abstract retrieved November 27, 2007, from EbscoHost Research Databases.
  7. ^ Strauss, R. (n.d.). Neonatal anemia: Pathophysiology and treatment. Transfusion Immunology and Medicine, 341-343. Retrieved December 10, 2007, from Google Scholar Research Databases.
  8. ^ Boxwell G. (2000). Chapter 8 hematological problems: Anemia. Neonatal Intensive Care Nursing, 164-187. Retrieved December 12, 2007, from EbscoHost Research Databases.
  9. ^ Dear, F., Gill, G., Newell, J., Richards, M., & Schwarz B. (2005). Effects of transfusion in anemia of prematurity. Pediatric Hematology and Oncology 22, 551-559. Retrieved December 9, 2007, from EbscoHost Research Databases.
  10. ^ Brown, M., & Keith, J. (1999). Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: A randomized trial. Pediatrics 104(2), 210-215. Retrieved November 27, 2007, from EbscoHost Research Databases.
  11. ^ Bain, A., & Blackburn, S. (2004). Issues in transfusing preterm infants in the NICU. Journal of Perinatal and Neonatal Nursing 18(2), 170-182. Retrieved December 4, 2007, from EbscoHost Research Databases.
  12. ^ Bishara N, Ohls RK (February 2009). "Current controversies in the management of the anemia of prematurity". Semin. Perinatol. 33 (1): 29–34. doi:10.1053/j.semperi.2008.10.006. PMID 19167579.